AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00450463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V/TRICOM
Description: A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
Study NCT04715750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-PI2620
Description: \[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
Study NCT02247206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy for Tics (CBIT)
Description: CBIT is an 8-session 10-week behavioral treatment for chronic tic disorders, including Tourette Syndrome. The first two sessions are 90 minutes, with subsequent sessions lasting 60 minutes. The treatment consists of Habit Reversal Training (awareness training, competing response training, and social support), and function-based assessment to reduce the impact of environmental or other stimuli on tic severity. The treatment also consists of relaxation techniques to reduce tic-related stress and tension, and behavioral rewards to motivate treatment compliance.
Study NCT03825562 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: acceptance and commitment therapy, ACT
Study NCT03825562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acceptance and commitment therapy, ACT
Study NCT01548586 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eldith DC stimulator ( Magstim Company Ltd. UK)
Description: Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
Study NCT01548586 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Eldith DC stimulator ( Magstim Company Ltd. UK)
Description: Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
Study NCT01885819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous stromal vascular fraction cells
Study NCT02224144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 1000 IU per day for 12 months
Study NCT02224144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 1000 IU per day for 12 months
Study NCT02224144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
Study NCT02224144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sugar pill) 1 pill per day for 12 months
Study NCT02014454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol eye drops
Description: All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularisation, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the ETROP Cooperative Group.
Study NCT00392509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALDH-br bone marrow cells vs. mononuclear bone marrow cells
Description: Surgery
Study NCT04197323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil liposomes for injection
Description: 40ug,once a day,continuous administration for 2 weeks
Study NCT04197323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprostadil liposomes for injection
Description: 40ug,once a day,continuous administration for 2 weeks
Study NCT01064622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT00013390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tinnitus Masking
Description: Tinnitus Masking is a widely-used method for providing relief of tinnitus. The central premise of Tinnitus Masking involves the use of wearable ear-level devices (hearing aids, maskers, or combination instruments) that deliver sound to a patient's ear(s). The primary purpose of the sound presentation is to produce a sense of relief from the annoyance caused by the tinnitus sound. The relief is accomplished by either obscuring, or covering up (masking) the tinnitus sound, or by changing the sound of the tinnitus in some way, usually by reducing its loudness (Vernon, Meikle).
Study NCT00013390 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tinnitus Retraining Therapy
Description: Tinnitus Retraining Therapy (TRT) was derived from a purely psychological approach for facilitating tinnitus habituation (Hallam et al). The current method is based on neurophysiological principles, and aims at retraining brain regions that are involved in processing the tinnitus signal, without attempting to suppress generation of the signal (Jastreboff). The retraining involves a systematic effort aimed at decreasing both the detectability of tinnitus and the transmission of the tinnitus signal to emotional centers of the brain. Habituation of tinnitus thus purportedly occurs at two levels: habituation of emotional reactions to the tinnitus and habituation of tinnitus perception. Habituation is achieved by utilizing directive counseling, along with the use of low-level broadband noise to reduce the detectability of tinnitus for patients with normal or near-normal hearing. When hearing loss is a significant problem to the patient, appropriate hearing aids are fitted.
Study NCT01064622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01064622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone/Placebo
Description: Given PO
Study NCT01064622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT02363764 — intervention group
Intervention type: PROCEDURE
Intervention: Nasal swab
Description: Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients
Study NCT02363764 — intervention group
Intervention type: PROCEDURE
Intervention: Cough swab
Description: Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients
Study NCT02363764 — intervention group
Intervention type: PROCEDURE
Intervention: Spontaneous expectorated sputum
Description: Will be obtained by the physiotherapist in:~- Expectorating CF patients
Study NCT02363764 — intervention group
Intervention type: PROCEDURE
Intervention: Induced sputum
Description: Will be obtained by the physiotherapist in:~* Non-expectorating CF patients~* Bronchoscopy CF patients
Study NCT02363764 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Will be obtained by the pulmonologist in:~- Bronchoscopy CF patients
Study NCT02363764 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Completing questionnaire on acceptability of different sampling methods by patients >6 years of age
Study NCT00533507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: Intramuscular injection, 3 doses.
Study NCT00533507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses.
Study NCT00533507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Oral, 2 doses.
Study NCT01426555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FES-Rowing
Description: FES- Rowing Exercise
Study NCT01426555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES-Rowing
Description: FES- Rowing Exercise
Study NCT01426555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 5 mg IV single dose
Study NCT03878069 — intervention group
Intervention type: BIOLOGICAL
Intervention: elapegademase-lvlr
Description: Revcovi is administered intramuscularly (i.m.). Weekly dosage is calculated in mg/kg of body weight, and can be adjusted over the course of the trial based on ADA activity and dAXP concentration as well as on clinical assessment by the treating physician.
Study NCT04167436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: A minimum of four weeks of prehabilitation with exercise three times a week, protein and vitamin supplements, dietitian consultation and medical optimization prior to surgery.
Study NCT01923389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg PF-05231023
Description: 100 mg IV infusion twice a week for 4 weeks
Study NCT04932720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chıld yoga programme
Description: Yoga sessions were in the form of 6 sessions and were held as 2 sessions per week. The program was given by an expert yoga instructor who has an international Yoga Alliance approved child and adolescent yoga certificate.Consisting of the components of Hatha Yoga (HY), one of the yoga types known and widely practiced all over the world; Sessions consisting of asanas (yoga postures), pranayamas (breathing techniques), relaxation, relaxation exercises and meditation were prepared. Sessions are 45 minutes; For those who are new to yoga for the first 15 minutes; mental and physical preparation; asanas, pranayamas were taught, drama followed by breathing exercises and asanas in the next 30 minutes, relaxation techniques (imaginary journey) and meditation in the last 15 minutes.
Study NCT02651285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G-CSF medium
Description: incubation of IVF embryos with a specific medium containing G-CSF
Study NCT02651285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: incubation of IVF embryos with a medium without G-CSF
Study NCT04079283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical
Description: Clinical: A diagnostic model incorporating clinical variables (Age, Pathological diagnosis, level of serum tumor biomarkers etc.)
Study NCT04079283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Semantic
Description: Semantic: A diagnostic model incorporating semantic radiological features (shape, location, border, density etc.)
Study NCT04079283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiomic
Description: Radiomic: A diagnostic model incorporating quantitative radiomic features (histogram, texture, morphology etc.)
Study NCT03075293 — intervention group
Intervention type: OTHER
Intervention: Determination of pain management
Description: Determine of pain management given to children with appendicitis in ER according to their medical records
Study NCT01038674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
Study NCT01038674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
Study NCT03680313 — intervention group
Intervention type: PROCEDURE
Intervention: Hypertension outpatient treatment
Description: Patients who have been diagnosed with primary hypertension and meet the conditions of the study will receive outpatient treatment
Study NCT01828203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Study NCT01828203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01828203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical spinal cord decompression
Description: Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.
Study NCT01828203 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgical spinal cord decompression
Description: Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.
Study NCT01828203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maintenance of minimum mean arterial pressure (MAP)
Description: Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
Study NCT01828203 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Maintenance of minimum mean arterial pressure (MAP)
Description: Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
Study NCT00464763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT00464763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00807495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib capsules
Study NCT03306407 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Improved hand hygiene
Description: The intervention group receives pre-travel advice with a special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
Study NCT00600743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSKI181771X (CCK-1R agonist)
Description: Drug one trial vs placebo
Study NCT00600743 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Instructions to binge eat
Description: Subjects will be instructed to binge eat and will also be given either drug or placebo
Study NCT00600743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructions to binge eat
Description: Subjects will be instructed to binge eat and will also be given either drug or placebo
Study NCT00600743 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Instructions to eat normally
Description: Subjects will be instructed to eat normally and will also be given either drug or placebo
Study NCT00600743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructions to eat normally
Description: Subjects will be instructed to eat normally and will also be given either drug or placebo
Study NCT04069936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MILs™ - NSCLC
Description: To evaluate the safety of MILs™ - NSCLC alone in subjects with locally advanced and unresectable or metastatic NSCLC
Study NCT04069936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab in subjects with locally advanced and unresectable or metastatic NSCLC
Study NCT04069936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC
Study NCT03961204 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data Collection
Description: No study treatment was administered as part of this study
Study NCT01193387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
Study NCT01411462 — intervention group
Intervention type: DEVICE
Intervention: VIBE + drug-eluting balloon
Description: VIBE before and after durg-eluting balloon angioplasty
Study NCT02736019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Women will receive oral Celecoxib 200mg 2 hours before the procedure
Study NCT02736019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive oral Tramadol 100 mg 2 hours before the procedure
Study NCT02736019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 1
Description: Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
Study NCT02736019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
Study NCT02736019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
Study NCT02736019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
Study NCT01770353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.
Study NCT02068651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance care planning programme
Description: It is a multi-faceted programme which includes an educational component with support of multimedia materials, reflection on personal values and a facilitated discussion between patient and family carer over future care. It will be delivered to each pair of participant and family carer on individual basis. By the end of the programme, each participant will have a personal workbook summarising the advance care planning process for record.
Study NCT03324139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
Study NCT03324139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
Study NCT03997799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uniportal lobectomy with complete lymphadenectomy
Description: uniportal lobectomy with complete lymphadenectomy
Study NCT02105220 — intervention group
Intervention type: OTHER
Intervention: Respiratory mechanics assessment
Description: Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.
Study NCT00045786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-1088
Description: 400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)
Study NCT01401062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresolimumab
Study NCT01401062 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT01229150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD6244
Description: For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
Study NCT01229150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
Study NCT01229150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD6244 + Erlotinib
Description: For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
Study NCT01513239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6072
Description: Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
Study NCT01513239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3415A
Description: Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
Study NCT01513239 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion of normal saline (0.9% sodium chloride)
Study NCT01513239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.